Statin therapy following percutaneous coronary revascularisation: time to make LIPS stick?

Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 38–AIC 40 Leave a comment
Click any image to enlarge
Authors:

The success of the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase inhibitors (statins) in ameliorating
atherothrombotic events is firmly established. Large
randomised controlled clinical trials have consistently (and
unequivocally) demonstrated a beneficial role in reducing
coronary events and total mortality in patients with advanced
coronary artery disease (CAD).








Advertisement

For UK healthcare professionals only


THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT